- Immune biomarkers in psychiatric illness: Findings from the biomarker subgroup of the NSAS Brain-Immune Interactions Workshop

Christopher Bartley,Giulia Lombardo,Manish K. Jha,Boris Chaumette,Jonas Hagenberg,Romain Rey,Marion Leboyer,Carmine M. Pariante
DOI: https://doi.org/10.1016/j.psyneuen.2023.106894
IF: 4.693
2024-02-01
Psychoneuroendocrinology
Abstract:Background Peripheral immune profiling studies have consistently identified inflammatory subgroups within primary psychiatric disorders such as major depressive disorder. However, clinical trials that have rationally selected immunomodulatory therapeutic agents have had mixed results, and few have stratified patients by immune biomarker status. Therefore, there are critical gaps in our knowledge about how peripheral inflammatory markers affect central immune status and which immune biomarkers can be used to inform clinical trial design. Methods Accordingly, we conducted a narrative review of immune biomarkers in psychiatric illness: circulating immune markers including C-reactive protein (CRP), non-human primate and human experimental studies of central immune responses to administration of peripheral immune molecules, inflammatory biomarker measurements in clinical trials, the utility of Mendelian randomization for ascribing causality to inflammatory biomarkers in depression, and the relationship between peripheral-central immune gene expression. Results Immune biomarker studies suggest that circulating immune markers can identify patients who would benefit from anti-inflammatory treatment and can inform selection of antidepressants. Although elevated CRP levels have been linked to poor response to SSRIs, other immune biomarkers may serve as better stratification indices for treatment trials. Detailed results from our findings will be discussed during the NSAS workshop (June, 2023) and presented at ISPNE. Conclusion We will synthesize our findings to identify: which immune biomarkers may be useful for patient stratification in clinical trials of depression and other psychiatric illnesses, unappreciated rational immune targets based on existing literature, and gaps in our understanding of immune biomarkers that should inform future experimental research studies.
neurosciences,endocrinology & metabolism,psychiatry
What problem does this paper attempt to address?